NeuroEndocrine Cancer Australia (NECA) has partnered with Oncidium, a non-profit, public-benefit organisation dedicated to advancing radioligand therapy for cancer care worldwide, to support World Radiotheranostics Day on 31 March 2026.
This partnership brings NECA into a global movement to raise awareness of radiotheranostics and the role of precision medicine in cancer care, while also sharing NECA resources with an international audience through the campaign.
Radiotheranostics, is not new in Australia however, it is an approach that allows doctors to both detect and treat cancer using targeted radioactive molecules, enabling more precise and personalised treatment. For people living with neuroendocrine cancer, these therapies can play an important role in improving outcomes and quality of life.
The partnership reflects a shared focus on increasing understanding of how these treatments work, ensuring commissioning bodies are informed, and advocating for equitable access so that patients who are eligible can receive appropriate care.
Despite its growing impact, awareness of radiotheranostics remains low. World Radiotheranostics Day aims to address this by raising public awareness, supporting patients and families, highlighting scientific innovation, and advocating for access to precision cancer treatments.
As part of the campaign, NECA is sharing a range of resources developed by Oncidium to support awareness across social media, newsletters and events.
To learn more and access resources, visit the World Radiotheranostics Day campaign website here.
